Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6233072 | 0.85 | RECQL (0.40) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL7073510 | 0.84 | TP53 (0.39) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL5098238 | 0.84 | MEN1 (0.41) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL5097715 | 0.82 | KMT2A (0.42) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL393138 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MEN1USP2KMT2ALMNA | |
| SCHEMBL6687431 | 0.80 | TP53 (0.39) | ALDH1A1MEN1USP2KMT2ALMNA | |
| SCHEMBL14095645 | 0.78 | CA12 (0.62) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL6689528 | 0.77 | MEN1 (0.39) | ALDH1A1MEN1USP2KMT2ALMNA | |
| SCHEMBL4894923 | 0.75 | CYP1A2 (0.42) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL27649383 | 0.74 | CHEK1 (0.37) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425552-B2 | Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction | ANADYS PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425552-B2 | Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction | ANADYS PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425552-B2 | Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction | ANADYS PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| CN-100376572-C | Anti-infective agents | ABBOTT LAB (US) | 2008-03-26 | — | — | CN | disclosed |
| EP-1348702-B1 | Method of producing 1, 2, 4-benzothiadiazine-1, 1-dioxide compound | FUJI PHOTO FILM CO LTD (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-20060189602-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| CN-1735612-A | Anti-infective agents | ABBOTT LAB (US) | 2006-02-15 | — | — | CN | disclosed |
| WO-2004052312-A2 | ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052313-A2 | ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| EP-1348702-A1 | Method of producing 1, 2, 4-benzothiadiazine-1, 1-dioxide compound | FUJI PHOTO FILM CO., LTD. (JP) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003059356-A2 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| US-6043017-A | HETEROCYCLIC COUPLERS ARE REACTED WITH COLOUR DEVELOPERS OF THE PHENYLENEDIAMINE AND/OR DIAMINOTOLUENE TYPE TO FORM COUPLING PRODUCTS WHICH EXHIBIT A STRONG ABSORPTION, PARTICULARLY IN THE INFRARED REGION. | AGFA-GEVAERT NV (BE) | 2000-03-28 | — | — | US | disclosed |
| US-5021330-A | Light sensitive silver halide emulsion layer | AGFA GEVAERT AKTIENGESELLSCHAFT (DE) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189602-A1 | Pyridazinone compounds | HAVCR2, PLPBP, CYP3A43 | ALDH1A1 1191/4885CA12 4845/4885CA1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.